- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Concord, California • Escondido, California + 46 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes, Type 2
- Interventions
- Community Health Worker Diabetes Education: Print media, CHW Diabetes Education: tailored web site
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Diabetes
- Interventions
- Dapagliflozin, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 49,790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
- Interventions
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetes
- Interventions
- Semaglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 742,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed Chronic Lymphocytic Leukemia
- Interventions
- Metformin
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type1diabetes
- Interventions
- Artificial Pancreas Controller in Dual Hormone Mode, Artificial Pancreas Controller in Single Hormone Mode, Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode, XeriSol glucagon
- Device · Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Type2Diabetes, ASCVD
- Interventions
- SGLT2 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 6,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 36
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin detemir, Insulin NPH, Diet/exercise
- Drug · Behavioral
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 19 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Sotagliflozin (SAR439954), Placebo
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 56
- States / cities
- Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Interventions
- Pioglitazone study drug, Placebo, Pioglitazone Open Label
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 30
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 26 more
- Conditions
- Cardiovascular Diseases, Diabetes
- Interventions
- SGLT2 inhibitor, GLP-1 RA, Education-First
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 27 Years to 79 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus
- Interventions
- Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Lymphedema
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Advanced Reconstructive Surgery Alliance
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Red Bank, New Jersey • Westwood, New Jersey
- Conditions
- Cushing's Disease, Acromegaly
- Interventions
- Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 15
- States / cities
- Multiple Locations, California • Torrance, California • Ventura, California + 10 more
- Conditions
- Type 2 Diabetes, Cardiac Disease
- Interventions
- Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 386,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Polycystic Ovary Syndrome, Obesity
- Interventions
- Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
- Drug
- Lead sponsor
- Woman's
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 119 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease
- Interventions
- Fasiglifam, Placebo, Antihyperglycemic therapy
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 7
- States / cities
- Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
- Conditions
- Diabetes
- Interventions
- Diabetes Medication Choice Decision Aid, Statin Choice Decision Aid, Usual care for lipid therapy medication, Usual care for antihyperglycemic medication
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 5
- States / cities
- Albert Lea, Minnesota • Austin, Minnesota • Kasson, Minnesota + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Dulaglutide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 13,299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Concord, California • Covina, California + 106 more
- Conditions
- Acute Kidney Injury
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 539,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- Insulin degludec, Insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 156
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 135 more
- Conditions
- Diabetes Mellitus, Type 2, Albuminuria
- Interventions
- Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 5,813 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 57
- States / cities
- Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more